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Abstract: Despite the initial efficacy of androgen deprivation in prostate cancer, virtually all
patients progress to castration-resistant prostate cancer (CRPC). Androgen receptor (AR) signaling
is critically required for CRPC. A new generation of medications targeting AR, such as abiraterone
and enzalutamide, has improved survival of metastatic CRPC (mCRPC) patients. However,
a significant proportion of patients presents with primary resistance to these agents, and in the
remainder, secondary resistance will invariably develop, which makes mCRPC the lethal form of
the disease. Mechanisms underlying progression to mCRPC and treatment resistance are extremely
complex. AR-dependent resistance mechanisms include AR amplification, AR point mutations,
expression of constitutively active AR splice variants, and altered intratumoral androgen biosynthesis.
AR-independent resistance mechanisms include glucocorticoid receptor activation, immune-mediated
resistance, and neuroendocrine differentiation. The development of novel agents, such as seviteronel,
apalutamide, and EPI-001/EPI-506, as well as the identification and validation of novel predictive
biomarkers of resistance, may lead to improved therapeutics for mCRPC patients.
Keywords: castration-resistant prostate cancer; androgen receptor; progression; resistance mechanisms;
enzalutamide; abiraterone
1. Introduction
In the United States, prostate cancer is the most commonly diagnosed malignancy (aside from
skin cancer), where approximately one out of every seven men will be diagnosed with the disease
during their lifetime [1]. It is estimated that 161,360 new cases of prostate cancer will be diagnosed in
2017 [1,2]. Overall survival (OS) for prostate cancer has improved over the past four decades, likely
due to a combination of early detection and diagnoses with improved treatment options. The 5-year
survival rate for prostate cancer (all stages combined) has risen from 68% to 99% [1,3]. The 10-year
survival rate is 98%, while the 15-year survival rate is 95% [3].
However, prostate cancer is still the third leading cause of cancer-related death among men
in the US. It is estimated that 26,730 deaths will occur in 2017 due to prostate cancer [2]. Despite
surgery or radiation, some patients (perhaps up to 20–30%) with clinically localized prostate cancer
will have recurrence of their disease after treatment and will progress to the metastatic stage over
time. For metastatic prostate cancer, androgen deprivation therapy (ADT) is the standard treatment,
and ADT can be achieved either by surgical castration through bilateral orchiectomy or medical
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castration through the use of luteinizing hormone-releasing hormone (LH-RH) agonists (i.e., leuprolide
acetate) or LH-RH antagonists (i.e., degarelix acetate). Despite its initial effectiveness in stabilizing
or causing regression of metastatic prostate cancer, progression to the lethal form of the disease,
known as castration-resistant prostate cancer (CRPC), is essentially inevitable for these patients.
CRPC can be defined as either progressively rising levels of serum tumor marker prostate-specific
antigen (PSA) or detection of new or progressive metastatic tumors by radiographic scans, despite
castrate testosterone levels (≤50 ng/dL). Based on recent preclinical and clinical data, it is now
evident that CRPC is not “androgen-independent” despite systemic depletion of androgens, but rather
continues to be dependent on the androgen receptor (AR) signaling axis [4,5]. Two new agents,
abiraterone and enzalutamide, have been recently approved by the U.S. Food and Drug Administration
(FDA), and have proven to be effective in the treatment of metastatic CRPC (mCRPC) [6–10].
However, many patients treated with these two agents will not experience a PSA response [6–9],
and nearly all of the remaining patients will eventually develop progression despite treatment [11].
Reactivation of the AR is central to the development and pathogenesis of CRPC, and treatment
resistance mechanisms may also be mediated by the AR signaling axis. Mechanisms that ultimately
alter AR axis signaling, disease progression, and/or lead to treatment resistance in CRPC can be
stratified into AR-dependent and AR-independent resistance mechanisms. AR-dependent resistance
mechanisms include AR amplification, AR point mutations, expression of constitutively active AR splice
variants, and altered intratumoral androgen biosynthesis. AR-independent resistance mechanisms
include glucocorticoid receptor overexpression, neuroendocrine differentiation, and immune-mediated
resistance mechanisms.
Ultimately, metastatic CRPC (mCRPC) remains incurable, and novel treatment resistance
mechanisms continue to be identified, implicating numerous, complex dysregulated molecular
signaling pathways that underlie the progression and lethality of the disease. The primary objective of
this review article is to discuss the etiologies underlying clinically-relevant mechanisms that lead to
drug resistance in mCRPC, and the potential treatment strategies designed to overcome resistance.
2. The Human Androgen Receptor
Normal differentiation of prostate cells is completely dependent on the AR, and in both
androgen-dependent prostate cancer and CRPC, the AR signaling axis plays a central role in disease
pathogenesis. The AR is a protein coding gene that is located on the X chromosome at Xq11–12,
is >90 kb in length, and consists of eight exons. It encodes the human AR protein, which is a member of
the steroid hormone receptor superfamily, and a ligand-activated nuclear transcription factor. The AR
is 110 kD, comprised of approximately 919 amino acids, and consists of four functional domains: (1) the
N-terminal transactivation domain (NTD); (2) the DNA-binding domain (DBD); (3) the hinge region;
and (4) the ligand-binding domain (LBD) [12–14]. The NTD (amino acids 1–537, encoded by exon 1) is
generally considered to be constitutively active, harbors transcriptional activation function-1 (AF-1),
and is critical for engaging the cellular transcription complex. Within the AF-1 are two transactivation
units (TAU): TAU-1 (amino acids 142–485) and TAU-5 (amino acids 351–528) [15]. Among the two,
TAU-5 is responsible for the majority of constitutive transcriptional activity, and has been associated
with aberrant AR activation in CRPC cells [16,17]. The DBD (amino acids 538–624, encoded by
exons 2 and 3) consists of two zinc finger domains that coordinate AR protein binding to specific DNA
sequences, and facilitate receptor homodimerization. The hinge region (amino acids 625–669, encoded
by exon 4) separates the DBD from the LBD, and contains the nuclear translocation signal, which is
necessary for AR nuclear import. The LBD (amino acids 626–919, encoded by exons 5–8), contains the
AF-2, and facilitates binding of androgen ligands, which act as the primary control mechanism of the
AR signaling axis (Figure 1) [12,16].
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Figure 1. The human androgen receptor gene and protein. This figure depicts the gene and protein 
structures for the AR-FL. The AR is located on the X chromosome (Xq11.2) and is comprised of eight 
exons. AR-FL contains the NTD (encoded by exon 1), the DBD (encoded by exons 2–3), the hinge 
region (encoded by exon 4) and the LBD (encoded by exons 5–8). The strong transcriptional activity 
in the NTD can be attributed to the AF-1, while the LBD contains the weaker AF-2. Two major 
transactivation units are present in the AF-1: TAU-1 and TAU-5. Abbreviations: AF-1, activation 
function 1; AF-2, activation function 2; AR-FL, androgen receptor full length; DBD, DNA-binding 
domain; LBD, ligand-binding domain; NTD, N-terminal transactivation domain; TAU-1, 
transactivation unit 1; TAU-5, transactivation unit 5; UTR, untranslated region. 
In the absence of dihydrotestosterone (DHT) binding to the AR, it remains isolated in an inactive 
form within the cytoplasm where it is bound to chaperone proteins (i.e., heat shock protein 90 or 
HSP90) [18]. In the absence of DHT activation, a nuclear export signal (NESAR) helps maintain 
cytoplasmic localization [19]. However, upon DHT-induced activation of the AR by binding to the 
LBD, NESAR activity is suppressed, and the AR disassociates from the chaperone complex, undergoes 
homodimerization, and translocates into the nucleus where it binds to androgen response elements 
(ARE) in cis-regulatory regions of target genes. AR binding to the AREs regulates transcription of 
genes that elicit biological responses as well as genes responsible for increased growth and survival 
of the prostate cancer (Figure 2) [18,20]. PSA transcription is predominantly regulated by the AR and 
therefore, serum PSA levels could be regarded as a surrogate marker of AR activity in tumor cells. 
When ADT is initiated, reduction in circulating testosterone reduces AR activity in prostate cancer 
cells and, correspondingly, the serum PSA level decreases. 
3. FDA-Approved Pharmacotherapeutics for mCRPC 
For over seven decades, ADT has been the cornerstone treatment for metastatic prostate cancer, 
and remains an indispensable treatment paradigm in mCRPC. Although ADT is initially effective in 
the majority of prostate cancer patients, its effects on tumor growth are transient, and most patients 
progress within 18–30 months [21]. AR reactivation, manifested by increasing PSA levels or disease 
progression despite effective testosterone suppression, drives progression to the lethal CRPC 
phenotype in virtually all patients. 
Prior to the FDA approval of abiraterone in 2011 and enzalutamide in 2012, mCRPC patients 
were traditionally treated with the microtubule-stabilizing taxane, docetaxel. Docetaxel was 
approved for the treatment of mCRPC based on two seminal phase III clinical trials (TAX 327 and 
SWOG 9916), both of which demonstrated a modest 2–3-month survival benefit to mCRPC patients 
[22,23]. After the approval of abiraterone and enzalutamide, docetaxel has largely been relegated to 
a second- or third-line treatment option for mCRPC. However, the recent ECOG 3805/CHAARTED 
and STAMPEDE phase III clinical trials demonstrated the effectiveness of docetaxel as a front-line 
option in patients with metastatic castration-sensitive prostate cancer [24,25]. 
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Figure 2. AR signaling axis, and mechanisms of AR targeted inhibition. CYP17A1 is the enzyme 
responsible for the conversion of androgen precursors (i.e., pregnenolone and progesterone; 
represented by the light purple circles) to DHEA, while HSD3β1 converts DHEA to AD, AKR1C3 
converts AD to testosterone (represented by the blue circles) and finally 5α-reductase converts 
testosterone to dihydrotestosterone (DHT; represented by the green circles). DHT-mediated 
activation of the AR causes a conformational change where the AR dimerizes, which then triggers AR 
translocation into the nucleus. Abiraterone selectively and irreversibly inhibits intratumoral 
androgen biosynthesis by potently blocking CYP17A1. As a result, less ligand is available for AR 
activation and AR axis signaling. Seviteronel (VT-464) is also an inhibitor of CYP17A1. Seviteronel 
has also been shown in preclinical models to have direct inhibitor effects on the AR. Enzalutamide is 
a potent second-generation antiandrogen that antagonizes the AR, prevents AR translocation into the 
nucleus, and inhibits AR-mediated transcription. Apalutamide (ARN-509) and darolutamide (ODM-
201) are also potent, competitive AR inhibitors with similar mechanisms of action to enzalutamide. 
EPI-506 reduces AR transcriptional activity by inhibiting protein-protein interactions between the AR 
and its transcriptional co-regulators. JQ1 is a bromodomain inhibitor that limits AR transcriptional 
ability by targeting its coactivators. Abbreviations: AD, androstenedione; AKR1C3, aldo-keto 
reductase family 1 member C3; AR, androgen receptor; CYP17A1, cytochrome P450 c17; DHEA, 
dehydroepiandrosterone; D, dihydrotestosterone; HSP, heat shock protein; HSD3β1, human 3-beta-
hydroxysteroid dehydroxynase/delta5-4 isomerase type 1; P, androgen precursors; PSA, prostate-
specific antigen; T, testosterone. 
Abiraterone blocks the production of intratumoral androgen biosynthesis by potently, 
selectively, and irreversibly inhibiting cytochrome P450 c17 (CYP17A1). CYP17A1 is central to 
androgen biosynthesis through both 17α-hydroxylase and C17,20-lyase activity [26]. Perhaps most 
importantly, CYP17A1 is the enzyme responsible for converting pregnenolone to 
dehydroepiandrosterone (DHEA; Figure 2) [27]. Potent and effective CYP17A1 inhibition ultimately 
limits the amount of circulating androgens available to activate the AR. Data from two seminal phase 
III clinical trials (COU-AA-301 and COU-AA-302) led to the FDA approval of abiraterone. The 
double-blinded, placebo-controlled COU-AA-301 trial was conducted in chemotherapy-pretreated 
mCRPC patients (n = 1195) [6]. COU-AA-301 met its primary endpoint by demonstrating that there 
was a 3.9-month longer median overall survival (OS) for patients treated with abiraterone (14.8 
versus 10.9 months), and a 35% reduction in the risk of death (hazard ratio (HR) = 0.65; 95% 
confidence interval (CI), 0.54–0.77; p < 0.001), when compared to placebo. Patients treated with 
abiraterone also exhibited significant improvements for all secondary endpoints such as radiographic 
Figure 2. AR signaling axis, and mechanisms of AR targeted inhibition. CYP17A1 is the enzyme
responsible for the conversion of androgen precursors (i.e., pregnenolone and progesterone; represented
by the light purple circles) to DHEA, while HSD3β1 converts DHEA to AD, AKR1C3 converts AD
to testosterone (represented by the blue circles) and finally 5α-reductase converts testosterone to
dihydrotestosterone (DHT; represented by the green circles). DHT-mediated activation of the AR
causes a conformational change where the AR dimerizes, which then triggers AR translocation into
the nucleus. Abiraterone selectively and irreversibly inhibits intratumoral androgen biosynthesis
by potently blocking CYP17A1. As a result, less ligand is available for AR activation and AR
axis signaling. Seviteronel (VT-464) is also an inhibitor of CYP17A1. Seviteronel has also been
shown in preclinical models to have direct inhibitor effects on the AR. Enzalutamide is a potent
second-generation antiandrogen that antagonizes the AR, prevents AR translocation into the nucleus,
and inhibits AR-mediated transcription. Apalutamide (ARN-509) and darolutamide (ODM-201)
are also potent, competitive AR inhibitors with similar mechanisms of action to enzaluta ide.
EPI-506 reduces AR transcriptional activity by inhibiting protein-protein interactions between
the AR and its transcriptional co-regulators. JQ1 is a bromodomain inhibitor that limits AR
transcriptional ability by targeting its coactivators. Abbreviations: AD, androstenedione; AKR1C3,
aldo-keto reductase fa ily 1 member C3; AR, androgen receptor; CYP17A1, cytochrome P450
c17; DHEA, dehydroepiandrosterone; D, dihydrotestosterone; HSP, heat shock protein; HSD3β1,
human 3-b ta-hy roxysteroid d hydroxynase/delta5-4 isomerase type 1; P, androgen precursors; PSA,
prostate-specific antigen; T, testosterone.
Abiraterone blocks the production of intratumoral androgen biosynthesis by potently, selectively,
and irreversibly inhibiting cytochrome P450 c17 (CYP17A1). CYP17A1 is central to androgen
biosynthesis through both 17α-hydroxylase and C17,20-lyase activity [26]. Perhaps most importantly,
CYP17A1 is the enzyme responsible for converting pregnenolone to dehydroepiandrosterone (DHEA;
Figure 2) [27]. Potent and effective CYP17A1 inhibition ultimately limits the amount of circulating
androgens available to activate the AR. Data from two seminal phase III clinical trials (COU-AA-301
and COU-AA-302) led to the FDA approval of abiraterone. The double-blinded, placebo-controlled
COU-AA-301 trial was conducted in chemotherapy-pretreated mCRPC patients (n = 1195) [6].
COU-AA-301 met its primary endpoint by demonstrating that there was a 3.9-month longer median
overall survival (OS) for patients treated with abiraterone (14.8 versus 10.9 months), and a 35%
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reduction in the risk of death (hazard ratio (HR) = 0.65; 95% confidence interval (CI), 0.54–0.77;
p < 0.001), when compared to placebo. Patients treated with abiraterone also exhibited significant
improvements for all secondary endpoints such as radiographic progression free survival (PFS), time to
PSA progression and PSA response rate. COU-AA-302 was a double-blinded, placebo-controlled trial
that was conducted in chemotherapy-naive mCRPC patients (n = 1088) [7]. COU-AA-302 achieved its
co-primary endpoints (OS and radiographic PFS). Investigators observed a 25% reduced risk of death
(HR = 0.75; 95% CI, 0.61–0.93; p = 0.01), a 47% reduced risk of progression (HR = 0.53; 95% CI, 0.45–0.62;
p < 0.001), and an increased median PFS by 8.3 months (16.5 versus 8.2 months) in abiraterone-treated
patients, when compared to placebo. Again, significant improvements were observed for all secondary
endpoints in patients treated with abiraterone. In both trials, excess mineralocorticoid-mediated
toxicities were significantly more common among the patients treated with abiraterone. Two recently
published clinical trials demonstrated that addition of abiraterone to ADT in metastatic prostate cancer
patients who are initiating ADT treatment resulted in substantial benefit, including increased OS and
PFS [28,29]. These data may lead to a major shift in standard of care treatment paradigms, where
abiraterone is initiated in hormone-sensitive patients. However, as more patients are exposed to
abiraterone during earlier stages of disease, complications related to secondary resistance will become
even more prominent in clinical practice.
Enzalutamide is a second-generation AR inhibitor that was developed to overcome resistance to
first-generation agents (i.e., bicalutamide or flutamide). Enzalutamide has a tri-modal mechanism of
action: (1) it potently binds to the AR LBD to prevent ligand binding and AR activation; (2) it inhibits
AR translocation into the cell nucleus; and (3) it prevents binding of AR to DNA to effectively inhibit
transcription of target genes (Figure 2). One of the main advantages of enzalutamide in mCRPC is that
is possesses no agonist properties in mCRPC with AR overexpression [30]. Data from two seminal
phase III clinical trials (AFFIRM and PREVAIL) led to the FDA approval of enzalutamide. AFFIRM
was a double-blinded, placebo-controlled trial conducted chemotherapy-pretreated mCRPC patients
(n = 1199) [8]. AFFIRM met its primary endpoint by demonstrating that median OS was 4.8 months
longer in patients treated with enzalutamide (18.4 versus 13.6 months), and the risk of death was
decreased by 37%, when compared to placebo (HR = 0.63; 95% CI, 0.53–0.75; p < 0.001). Significant
improvements in all secondary endpoints were also observed among patients in the enzalutamide arm.
PREVAIL was a double-blinded, placebo-controlled trial conducted in chemotherapy-naıve mCRPC
patients (n = 1717) [9]. PREVAIL achieved both of its co-primary endpoints (OS and radiographic PFS).
Investigators observed a 2.2 month longer median OS (32.4 versus 30.2 months), and a 29% reduced
risk of death (HR = 0.71; 95% CI, 0.60–0.84; p < 0.001). Second, radiographic PFS was also superior
for patients in the enzalutamide arm, with an 81% reduced risk of progression (HR = 0.19; 95% CI,
0.15–0.23; p < 0.001). Similar to AFFIRM, patients in the PREVAIL enzalutamide arm also achieved
significant improvements in all secondary endpoints.
The pharmacotherapeutic landscape for the treatment of mCRPC has been further expanded
over the last decade with the FDA approval of three new agents. Options for the treatment of
mCRPC now include: (1) the autologous cellular immunotherapy, sipuleucel-T, for asymptomatic or
minimally symptomatic mCRPC patients (approved by the FDA in 2010) [31]; (2) the semi-synthetic
taxane, cabazitaxel, which was shown to be effective in overcoming secondary resistance to docetaxel
(approved by the FDA in 2010) [32]; and (3) the α-emitting radiopharmaceutical, radium-223 (approved
by the FDA in 2013) [33]. However, resistance mechanisms for these agents will not be discussed,
as they are beyond the focus of this review. Despite the availability of enzalutamide and abiraterone
for CRPC patients, secondary resistance mechanisms inevitably result in clinical progression. Novel
therapeutics that target altered intratumoral androgen biosynthesis (i.e., seviteronel [34]) or the AR with
greater affinity and potency (i.e., apalutamide and darolutamide [35,36]), as well as those that degrade
the AR (i.e., niclosamide [37]) or target the AR NTD (i.e., EPI-506 [38,39]) are currently in development
for the treatment mCRPC (Figure 2). These currently investigational pharmacotherapeutics will be
discussed in more detail in the following sections.
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4. AR-Dependent Resistance Mechanisms
Although abiraterone and enzalutamide have advanced the treatment of mCRPC patients,
approximately 20–40% of patients present with primary resistance to these agents (e.g., no initial
PSA response) [6–8,40]. Moreover, patients who do experience a clinical or biochemical response after
treatment with these two agents will eventually develop secondary resistance to the drug [11]. Despite
distinct mechanisms of drug action, there may be significant cross-resistance between abiraterone
and enzalutamide [41,42]. One plausible hypothesis of cross-resistance between the two drugs
centers on the recent finding that an active metabolite of abiraterone (∆4-abiraterone) has potent
AR antagonist properties. The mechanisms of drug action that are similar between ∆4-abiraterone and
enzalutamide could also be shared resistance mechanisms that explain the cross-resistance between
the two drugs [43].
Primary and secondary resistance to abiraterone and enzalutamide are extremely complex [44].
Mechanisms of resistance that are mediated by the AR include (but are likely not limited to):
AR amplification, AR overexpression, AR somatic point mutations, constitutively active AR splice
variants, and altered intratumoral androgen biosynthesis [18,45–47].
4.1. AR Amplification and Overexpression
AR amplification and overexpression are two primary etiologies for progression to the mCRPC
phenotype, and are likely important to the development of treatment resistance. While not generally
present in hormone-sensitive cells, up to 80% of CRPC cells exhibit AR amplification, AR mRNA
overexpression, or AR protein overexpression [48,49]. AR amplification, leading to AR overexpression,
enables progression to CRPC even in the setting of low circulating androgens due to ADT
treatment [50].
In addition to its role in mCRPC progression, there is mounting evidence that AR
amplification could also be an important resistance mechanism. Preclinical in vitro studies using
enzalutamide-resistant LNCaP cells express higher levels of AR (and AR splice variants) when
compared to naïve LNCaP cells [51]. One in vivo study showed 3-fold increased AR expression
after CRPC xenografts were treated with abiraterone [52]. Finally, a recent study that utilized liquid
biopsies and circulating tumor DNA (ctDNA) to probe the AR genomic landscape discovered that
patients with AR amplification were less likely to respond to treatment. A total of 50% of patients
who were pretreated with either enzalutamide or orteronel (a CYP17A1 inhibitor) prior to abiraterone
treatment showed evidence of AR amplification, and only 13% of those with AR gain demonstrated a
response with ≥50% PSA decline after being treated with abiraterone [53]. A separate study, using
circulating tumor cells (CTCs), examined AR amplification as a resistance mechanism in mCRPC
patients treated with abiraterone or enzalutamide, and who had received previous docetaxel treatment.
Among the patients in the study discovery cohort who had received docetaxel (n = 98), AR amplification
was associated with a worse rate of PSA decline of ≥50%, shorter PFS (HR = 1.95; 95% CI, 1.23–3.11;
p < 0.01), and shorter OS (HR = 3.81; 95% CI, 2.28–6.37; p < 0.001). These results were confirmed in
their replication cohort of enzalutamide-treated patients from the PREMIERE trial (n = 100), where
patients with AR amplification experienced shorter PSA PFS (HR = 4.33; 95% CI, 1.94–9.68; p < 0.001),
and OS (HR = 11.08; 95% CI, 2.16–56.95; p < 0.004) [54]. Additional studies of liquid biopsies have
also demonstrated that AR amplification in ctDNA is associated with resistance to abiraterone and
enzalutamide [55,56].
4.2. AR Point Mutations
In CRPC, AR mutations are found in 5–30% in tumors, CTCs, and ctDNA [53,55,57]. AR point
mutations confer resistance to enzalutamide and abiraterone, but currently there is some ambiguity as
to whether the spectrum of somatic mutations that confer drug resistance are different for abiraterone
and enzalutamide. The majority of clinically-relevant somatic point mutations in the AR is located in
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the LBD. These include four main somatic missense mutations: (1) a leucine to histidine substitution
at amino acid 702 (L702H); (2) a histidine to tyrosine substitution at amino acid 875 (H875Y);
(3) a phenylalanine to leucine substitution at amino acid 877 (F877L); and (4) a threonine to alanine
substitution at amino acid 878 (T878A) (Figure 3).Cancers 2017, 9, 67 7 of 18 
 
 
Figure 3. AR somatic missense mutations. The main four missense mutations that are focused on in 
this review all occur in the AR LBD (AR exons 5–8) and include: L702H, H875Y, F877L (previously 
published as F876L), and T878A (previously published as T877A). Abbreviations: DBD, DNA binding 
domain; LBD, ligand binding domain; NTD, N-terminal transactivation domain. 
One of the most frequently reported AR point mutations is T878A (previously reported in the 
literature as T877A), which is a gain of function mutation, and can be activated by both steroid 
hormones (e.g., progesterone) and first-generation antiandrogens (e.g., bicalutamide or flutamide). It 
most commonly arises after treatment with abiraterone because when CYP17A1 is effectively 
inhibited, intracellular progesterone levels increase, while DHEA and testosterone are suppressed. 
Intuitively, it would appear that this mutation would effectively limit AR activation; however, the 
T878A mutation broadens ligand binding specificity of the AR so that it can be activated by 
progesterone, glucocorticoids, and estrogen [58]. Thus, the T878A mutation creates malignant clones 
that are able to overcome abiraterone inhibition [59]. A recent study of abiraterone-treated mCRPC 
patients revealed that the T878A mutation was detected in 3 of 18 patients at high frequency [60]. 
A second frequently reported somatic mutation, F877L (previously reported in the literature as 
F876L), arises in patients after treatment with enzalutamide or apalutamide. Apalutamide (formerly 
ARN-509) and darolutamide (formerly ODM-201) have a similar mechanism of action to 
enzalutamide [35,36]. There is evidence that darolutamide could more potently antagonize the AR 
than enzalutamide [36]. In preclinical models, both have shown less blood–brain barrier penetration 
than enzalutamide, which could therefore spare patients the central nervous system-mediated 
adverse events (i.e., seizures) associated with enzalutamide [35,36]. Preclinical data from prostate 
cancer cell lines and patient tumor tissues revealed that F877L can effectively convert enzalutamide 
from a potent antagonist into a partial agonist [61–63]. Another preclinical study demonstrated that 
F877L can occur spontaneously in enzalutamide-treated cells, suggesting that this could be an 
important secondary resistance mechanism for second-generation AR antagonists [62]. Spontaneous 
F877L mutations were also detected in ctDNA of patients treated with apalutamide or enzalutamide 
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One of the most frequently reported AR point mutations is T878A (previously reported in the
literature as T877A), which is a gain of function mutation, and can be activated by both steroid
hormones (e.g., progesterone) and first-generation antiandrogens (e.g., bicalutamide or flutamide).
It most commonly arises after treatment with abiraterone because when CYP17A1 is effectively
inhibited, intracellular progesterone levels increase, while DHEA and testosterone are suppressed.
Intuitively, it would appear that this mutation would effectively limit AR activation; however,
the T878A mutation broadens ligand binding specificity of the AR so that it can be activated by
progesterone, glucocorticoids, and estrogen [58]. Thus, the T878A mutation creates malignant clones
that are able to overcome abiraterone inhibition [59]. A recent study of abiraterone-treated mCRPC
patients revealed that the T878A mutation was detected in 3 of 18 patients at high frequency [60].
A second frequently reported somatic mutation, F877L (previously reported in the literature
as F876L), arises in patients after treatment with enzalutamide or apalutamide. Apalutamide
(formerly ARN-509) and darolutamide (formerly ODM-201) have a similar mechanism of action
to enzalutamide [35,36]. There is evidence that darolutamide could more potently antagonize the AR
than enzalutamide [36]. In preclinical models, both have shown less blood–brain barrier penetration
than enzalutamide, which could therefore spare patients the central nervous system-mediated adverse
events (i.e., seizures) associated with enzalutamide [35,36]. Preclinical data from prostate cancer
cell lines and patient tumor tissues revealed that F877L can effectively convert enzalutamide from a
potent antagonist into a partial agonist [61–63]. Another preclinical study demonstrated that F877L
can occur spontaneously in enzalutamide-treated cells, suggesting that this could be an important
secondary resistance mechanism for second-generation AR antagonists [62]. Spontaneous F877L
mutations were also detected in ctDNA of patients treated with apalutamide or enzalutamide [55,61].
However, darolutamide has been shown, preclinically, to be resistant to both T878A and F877L point
mutations [36], which might make it an attractive option for patients who develop secondary resistance
to enzalutamide. Additional preclinical data has revealed that the nonsteroidal CYP17 inhibitor
seviteronel (formerly VT-464) cannot only potently antagonize the AR, but it can also overcome F877L
mutations that arise after treatment with enzalutamide or abiraterone [34,64,65].
Interestingly, L702H is a mutation that can result in glucocorticoid-mediated activation of the AR.
In one study, the L702H mutation was associated with primary resistance to abiraterone [66]. Another
study demonstrated that both L702H and T878A point mutations were associated with poor PSA
response after abiraterone or enzalutamide treatment. Among patients with aberrant AR who were
treated with enzalutamide, only 13% experienced a ≥50% PSA decline after abiraterone treatment [53].
Another recent study demonstrated that abiraterone-treated patients harboring either the T878A or
the L702H mutation experienced shorter OS (HR = 3.26; 95% CI, 1.47–not reached; p < 0.004), when
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compared to patients without detectable point mutations. In this study, T878A and L702H mutations
were only found in patients who had received prior docetaxel treatment [54].
4.3. AR Splice Variants
Approximately 20 AR mRNA splice variants (AR-V) have been identified since 2008. While
select AR-Vs are only conditionally active (i.e., AR-V1 and AR-V9) [67], many are constitutively active
(i.e., androgen-independent nuclear localization to promote transcription of target genes) [68], and are
likely to be a clinically-relevant mechanism of secondary resistance in mCRPC patience who have
been treated with abiraterone or enzalutamide. While most AR-Vs retain the NTD and DBD domains,
alternative splicing of AR-V7 results in the addition of a cryptic exon 3. In ARv567es, alternate splicing
leads to skipping of exon 5, 6, and 7, and a frameshift that causes a premature stop codon in exon 8.
Both splice variants cause the loss of the LBD domain, and the formation of the C-terminal truncated
protein (Figure 4) [69–71].
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AR-V expression has been associated with both enzalutamide and abiraterone resistance.
In preclinical xenograft models, it was shown that expression of AR-V7 and ARv567es can be
induced by abiraterone. In one study that demonstrated an OS advantage in mice treated with
abiraterone, AR-V7 and ARv567es expression was increased 3.1-fold and 5.2-fold, respectively [52].
Similarly, increased splice variant mRNA expression was discovered in mouse xenograft models of
enzalutamide-resistance [52,72].
Clinically, ARv567es and AR-V7 are likely to be the active in mCRPC, and most relevant to
enzalutamide and abiraterone resistance. Early studies revealed that expression levels of ARv567es
and AR-V7 were correlated with poorer survival in patients [73]. Moreover, AR-V7 may be a
predictive biomarker of secondary resistance and poor outcomes in mCRPC that will inform treatment
selection, and aid in future development of therapeutics. A recent study (n = 62), utilizing a CTC
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assay, demonstrated that AR-V7 mRNA expression is associated with enzalutamide and abiraterone
secondary resistance [11]. In this study, CTCs from 31% of the enzalutamide-treated patients and 19% of
the abiraterone-treated patients demonstrated detectable AR-V7 mRNA expression. Patients who were
treated with either enzalutamide or abiraterone, and were positive for AR-V7, achieved significantly
lower rates of PSA response, and experienced significantly shorter PFS and OS. This observation could
also provide an additional mechanism of cross-resistance between these two agents. Interestingly,
AR-V7 mRNA expression can increase from baseline in patients treated with either taxanes, abiraterone,
or enzalutamide, but a decline in AR-V7 levels was only observed in patients treated with a taxane [74].
Additionally, a separate study that used CTCs to detect AR-V7 mRNA revealed that patients with
detectable AR-V7 may benefit more from taxane treatment, when compared to either abiraterone or
enzalutamide treatment [75]. These data suggest that patients maintain sensitivity to taxanes, despite
the presence of detectable AR-V7 mRNA, which means that taxanes remain a viable treatment option
for patients who progress on abiraterone and/or enzalutamide.
All of the current FDA-approved medications target the LBD, but it is the NTD that
contains the transcriptionally active portion of the AR (AF1). Because clinically-relevant
AR-Vs, such as ARv567es and AR-V7, confer resistance, compounds that degrade the AR
(i.e., niclosamide [37,76], or even galeterone [77] as a proof of concept), prevent AR-mediated
transcription (i.e., bromodomain-containing protein 4 (BRD4) inhibitors like JQ1 [78]), or target the
AR NTD (i.e., sintokamides [79] or EPI-506 [38,39]) could be viable treatment options after patients
progress on abiraterone and/or enzalutamide.
Niclosamide is an FDA-approved anti-helminthic drug that was shown in preclinical models
to be particularly effective at targeting AR-V7 through proteasome-dependent downregulation of
AR-V7 protein expression, and inhibition of AR-V7 transcriptional activity through reduced AR-V7
recruitment to the PSA promoter. In addition, the combination of niclosamide and enzalutamide was
shown to inhibit tumor growth in enzalutamide-resistant in vitro models, indicating that niclosamide
may be a viable option to overcome secondary resistance to enzalutamide in mCRPC [37]. Moreover,
the combination of niclosamide and abiraterone was also shown to resensitize abiraterone-resistant
AR-V7 cells in both in vitro and in vivo preclinical models of CRPC [76].
EPI-506 is a prodrug of one of the four stereoisomers of its predecessor, EPI-001. EPI-506 binds to
the AF1 region, and thereby effectively blocks the NTD, inhibits AR transcriptional activity by reducing
protein–protein interactions between the AR and co-activators, and prevents NTD transactivation [38,
39]. This mechanism conceivably allows EPI-506 to overcome the common secondary resistance
mechanisms germane to agents that target the LBD. Preclinically, analogs of EPI-001 were able to
inhibit transcription of cells with full-length AR, as well as those with the ARv567es splice variant.
These analogs of EPI-001 inhibited the growth of xenograft tumors that express AR splice variants
lacking the LBD [39]. Currently, a phase I/II study with EPI-506 is underway to evaluate the safety
and efficacy or EPI-506 in treatment-naïve mCRPC patients, and also those who have progressed on
enzalutamide or abiraterone (NCT02606123). Correlative studies using CTCs will assess the efficacy of
EPI-506 in patients with detectable levels of AR-V7 mRNA.
An alternative approach to bypass secondary resistance mechanisms involving AR splice variants
is to target co-activators or co-repressors involved in AR-mediated transcription. Numerous molecules
that act as either co-activators or co-repressors of the AR, to modulate its transcriptional activity, have
been identified [80]. Specifically, the AR co-activator BRD4 is a potential pharmacotherapeutic target
in mCRPC. BRD4 recruits RNA polymerase II (RNA PolII) and the transcription elongation factor
P-TEFb to promote transcription. JQ1 competitively binds to BRD4, displaces it from active chromatin,
and removes RNA PolII from target genes [81]. One preclinical study showed that JQ1 prevented
BRD4 binding to the AR NTD, and thus mediated inhibition of AR binding to chromatin enhancer
sites. But more importantly, this study demonstrated that JQ1 effectively inhibited AR-V7 and ARv567es
mRNA and protein expression [82]. Then, in a second preclinical study, a panel of prostate cancer
cell lines were shown to be sensitive to JQ1-mediated cell cycle arrest and apoptosis. Treatment of
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enzalutamide-resistant VCaP cells resulted in transcriptional downregulation of AR target genes.
Perhaps most importantly, in mouse xenograft models of treatment resistance where elevated levels of
AR-V7 were detected, JQ1 monotherapy (or in combination with enzalutamide) effectively delayed
tumor progression, and showed robust silencing of AR-V7 [81]. These data point to the potential
of bromodomain inhibitors to overcome secondary treatment resistance mechanisms mediated by
expression of AR splice variants.
4.4. Altered Steroidogenesis
It is likely that extended treatment with either abiraterone or enzalutamide induces alterations
to intratumoral androgen biosynthesis. As a result, increased circulating androgens, combined with
mutations (germline and/or somatic) that affect metabolizing enzyme expression or function, promote
AR reactivation and progression to mCRPC. For instance, enzalutamide-resistant cell lines were found
to have upregulated androgens, and over-expressed genes involved in androgen biosynthesis [83].
Multiple gene expression studies have identified significantly increased levels of SRD5A1, HSD3β1,
and AKR1C3 in CRPC tissues [84–86]. Enzalutamide-resistant xenograft tumors revealed increased
protein aldo-keto reductase family 1 member C3 (AKR1C3) protein expression [83]. Abiraterone-treated
xenografts with the gain-of-function N367T missense mutation (asparagine to threonine substitution
at amino acid 367) in HSD3B1 were resistant to ubiquitination and degradation, which led to DHT
accumulation [87]. Finally, abiraterone-treated tumor xenografts revealed 2-fold upregulation of
CYP17A1 [52], and cell-free CYP17A1 copy number variations were associated with poorer outcomes
in abiraterone-treated patients [88].
5. AR-Independent Resistance Mechanisms
In addition to AR-mediated resistance mechanisms, there are several AR-independent resistance
mechanisms that lead to treatment failure, as well as progression of mCRPC. Glucocorticoid receptor
overexpression, neuroendocrine differentiation, and immune-mediated resistance have also been
implicated in treatment resistance in CRPC [58,89,90].
5.1. Glucocorticoid Receptor Activation
The role of glucocorticoids and the glucocorticoid receptor (GR) in prostate cancer is complex
because glucocorticoids can be both beneficial and harmful. However, in mCRPC where ADT is
used to antagonize AR signaling, GR upregulation and activation can be another clinically-relevant
mechanism of resistance to therapeutics that target the AR signaling axis.
The AR and GR are both members of the same class of nuclear steroid receptors, share common
structures and mechanisms of action [58], have highly homologous DBDs [91], and have overlapping
transcriptomes [92].
As patients progress to mCRPC, the reliance on direct AR signaling is bypassed as a result of
potent receptor inhibition, which causes subsequent activation of the GR. Activated GR is then able to
bind to nuclear AREs and regulate a subset of AR target genes that promote cell survival and tumor
progression [92,93]. One recent preclinical study provided evidence showing GR-driven resistance in
two independent in vitro models (LNCaP/AR and VCaP cells). This study also showed increased GR
expression was associated with both enzalutamide and apalutamide resistance. In addition, the authors
also demonstrated that GR knockout in VCaP cells could restore sensitivity to enzalutamide [92].
A separate preclinical study using chromatin immunoprecipitation (ChIP) combined with deep DNA
sequencing revealed that GR protein expression is negatively controlled by AR signaling. In addition,
xenograft models from this study also showed that GR mRNA and GR protein expression increased in
the presence of AR knockdown or AR antagonists [91]. Moreover, in vitro models have also revealed
that GR overexpression was associated with docetaxel resistance, and that GR antagonism could
resensitize docetaxel-resistant prostate cancer cells [94].
Cancers 2017, 9, 67 11 of 19
Data from these publications support the hypothesis that GR activation and upregulation,
secondary to AR antagonism, is a potential resistance mechanism to therapies targeting the AR
axis. Further investigations with analyses of pre-treatment patient samples (i.e., blood), as well as
samples at the point of treatment progression, are necessary to characterize the extent to which GR
activation and upregulation contributes to secondary resistance in mCRPC.
5.2. Immune-Mediated Resistance Mechanisms
Despite FDA approval of several immunotherapies for a variety of malignancies within the
past three years, the role of checkpoint inhibitors for the treatment of mCRPC has yet to be fully
elucidated. Primarily, this was based on negative results from studies involving the CTLA-4
inhibitor, ipilimumab [95]. However, a recent analysis of PD-L1 expression was performed in two
independent, well-characterized prostate cancer cohorts. In the discovery cohort (n = 209), moderate
to high PD-L1 expression in prostatectomy specimens was associated with tumor progression (Ki-67,
p < 0.001), Gleason score (p = 0.004), AR expression (p < 0.001), and was prognostic for biochemical
recurrence (HR = 2.37; 95% CI, 1.32–4.25; p = 0.004). In the replication cohort (n = 611), associations
between PD-L1 and AR expression, and proliferation were confirmed (p < 0.001). Furthermore,
the association between PD-L1 expression and biochemical recurrence was confirmed in a multivariate
model (HR = 1.46; 95% CI, 1.11–1.92; p = 0.007) [96]. Recent preclinical in vitro and in vivo studies
have revealed that PD-L1 is significantly expressed in enzalutamide-resistant cell lines, and that
mice with enzalutamide-resistant tumors also experienced detectable circulating PD-L1 levels [97].
Results from these studies support the hypothesis that mCRPC progression and resistance to AR
signaling axis inhibitors may be mediated by PD-L1 and PD-1. To further support this hypothesis,
a phase II clinical trial is underway to investigate the use of the PD-1 inhibitor pembrolizumab
(in combination with enzalutamide) in mCRPC patients who developed secondary resistance to
enzalutamide (NCT02312557). Initial results from the first 10 patients enrolled on the trial have
recently been published, and showed that three of these patients experienced rapid PSA reductions
(≤0.2 ng/mL), and two of the three achieved a partial response [98].
There are two additional ongoing phase II trials exploring the role of immunotherapy in mCRPC.
One of the two trials is evaluating ipilimumab in combination with abiraterone in treatment-naïve
mCRPC patients (NCT01848067), and could conceivably answer important hypotheses pertaining to
primary resistance. More importantly, the second trial is evaluating combination immune checkpoint
blockade with ipilimumab and the PD-1 inhibitor nivolumab in mCRPC patients positive for AR-V7
(NCT02601014). This second trial has the potential to be informative from the perspective of using a
predictive biomarker for the purpose of treatment selection, and also for understanding the role of
immunotherapy in pre-treated mCRPC patients.
5.3. Neuroendocrine Differentiation
While only approximately 1% of all primary prostate cancers are diagnosed as neuroendocrine
prostate cancer (NEPC), up to 30% of mCRPCs are NEPC [99]. The progression of prostate cancer
adenocarcinoma (PCA) to NEPC has become increasingly appreciated recently as an important
mechanism of treatment resistance, which ultimately results in transition to an extremely lethal
prostate cancer subtype. This profound phenotypic switch, as a consequence of selective pressure from
ADT or potent antiandrogens, from tumors with adenocarcinoma histologic features that express AR to
AR-negative neuroendocrine prostate tumors, has been termed lineage plasticity. This situation
is somewhat analogous to the emergence of small cell lung cancer in epidermal growth factor
receptor-mutant adenocarcinoma treated with the inhibitor of epidermal growth factor receptor [100].
In a study of metastatic biopsies from 81 prostate cancer patients (n = 51 PCA, and n = 30 NEPC), whole
exome sequencing showed that molecular signatures and gene copy numbers were similar between
the two prostate cancer subtypes, confirming that NEPC is derived from PCA precursors [101]. Until
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recently, selection of appropriate and effective treatments for NEPC has been thwarted by a poor
understanding of molecular drivers of lineage plasticity in prostate cancer.
Loss or mutation of both TP53, which encodes the p53 tumor suppressor protein, and RB1, which
encodes the retinoblastoma tumor suppressor protein, have emerged as two important factors in
NEPC differentiation [102,103]. In one study, RB1protein loss was observed in 90% of NEPC tumors,
and RB1 deletions in 85% of cases [104]. A recent preclinical in vivo mouse study revealed that Rb1
loss facilitates lineage plasticity and metastasis in PCA with Pten loss, and Trp53 causes secondary
resistance to therapies targeting the AR signaling axis [105]. A second preclinical study, using in vitro
and in vivo human prostate cancer models, demonstrated evidence of lineage plasticity, and a shift
from androgen-dependent PCA to androgen-independent NEPC after treatment with enzalutamide.
This phenotypic switch was facilitated by loss of TP53 and RB1, and was mediated by increased
expression of a transcription factor named SOX2. They also showed that inhibition of SOX2 restored
TP53 and RB1 function [106].
Genomic amplification and overexpression of MYCN, which encodes N-Myc, and AURKA, which
encodes Aurora kinase A, are also associated with differentiation from PCA to NEPC [104,107,108].
Two studies showed that amplifications of both MYCN and AURKA occurred in between 40–86% of
pretreated NEPC samples and metastases, compared to only 5% of PCAs [107,108]. Another recent
study showed that PCA and NEPC arise from a common epithelial clone, that N-Myc is an NEPC
driver, and that inhibition of Aurora kinase A destabilizes N-Myc [109]. In another preclinical study,
N-Myc abrogated AR signaling, and N-Myc protein overexpression drove an aggressive cancer that is
molecularly similar to human NEPC. In this study, Aurora kinase A knockdown, or treatment with the
Aurora kinase A inhibitor alisertib (formerly MLN8237) resulted in decreased N-Myc protein levels,
N-Myc target gene expression, and cell viability [110].
There are currently no therapeutics in the drug development pipeline that target TP53 or RB1
genomic loss or mutations. However, a phase II trial is underway, which is evaluating the safety and
effectiveness of alisertib in mCRPC and NEPC patients (NCT01799278). A second Aurora kinase A
inhibitor, CD532, was shown to reduce N-Myc protein levels in preclinical models driven by MYCN,
which indicates this could conceivably be a viable treatment option for NEPC patients in the future if
the drug is moved into clinical trials [109].
6. Conclusions
Nearly all patients with metastatic prostate cancer who are initially treated with ADT will
progress to mCRPC, mainly due to reactivation of the AR signaling axis. Because of myriad
adaptive resistance mechanisms, mCRPC remains incurable despite the development and FDA
approval of novel agents that target the AR signaling axis. However, the identification and a
more comprehensive understanding of AR-dependent (i.e., AR amplification, AR point mutations,
expression of constitutively active AR splice variants, and altered intratumoral androgen biosynthesis),
and AR-independent mechanisms (i.e., glucocorticoid receptor activation and upregulation,
neuroendocrine differentiation, and immune-mediated resistance) will allow for the design and
implementation of novel pharmacotherapeutic treatment paradigms in patients with mCRPC.
Moreover, the development, validation and clinical implementation of assays (i.e., liquid biopsies) will
be useful in identifying mechanisms of resistance, can conceivably provide clinically relevant predictive
biomarkers, and will become essential tools that help clinicians identify the optimal treatment for a
given patient.
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